Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

Intellia Therapeutics

Vir Biotechnology

Vertex Pharmaceuticals

Zoetis

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Endo (ENDP) Keep the Earnings Surprise Streak Alive?

DUBLIN , May 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "We look forward to further developing and bringing these durable and differentiated products to market—and to the healthcare providers and patients who need them.

Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Endo International (ENDP) to Report a Decline in Earnings: What to Look Out for

DUBLIN , April 20, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals has reversed a trial court judge's order denying a motion for recusal by Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, Endo or the Company) in  Clay County et al. v. Purdue Pharma, L.P.

Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo

DUBLIN, April 12, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 8947159.

Endo to Announce First-Quarter 2022 Financial Results

Endo International (ENDP) closed at $2.31 in the latest trading session, marking no change from the prior day.

Endo International (ENDP) Flat As Market Gains: What You Should Know

Endo (ENDP) reported earnings 30 days ago. What's next for the stock?

Why Is Endo (ENDP) Up 4.6% Since Last Earnings Report?

CVS Health

Teva Pharmaceutical

Allergan

Florida has reached more than $878 million of settlements with CVS Health Corp and three drug companies to resolve claims over their roles in fueling an opioid epidemic in the third most populous U.S. state.

Florida reaches $878 million opioid settlements with CVS, Teva, others

DUBLIN , March 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial. "We are pleased to launch this new ready-to-use product as part of our agreement with Nevakar," said Scott Sims, Senior Vice President and General Manager, Sterile Products at Endo.

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials

Why bother buying shares of heavily indebted companies with receding revenue?

Investing in Biopharma? Avoid These 2 Stocks

DUBLIN, March 3, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program.   "At Endo, we are motivated by a strong sense of purpose.

Endo Launches New Living Our Values Program to Recognize Outstanding Team Members

DUBLIN, March 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) has kicked off a series of more than 200 patient events that will be held across the United States as part of Butt First, a new direct-to-consumer awareness campaign designed to excite and educate women about Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes). QWO received FDA approval in July 2020 and is the first and only injectable treatment for moderate to severe cellulite in the buttocks of adult women.

Butt First: Endo Launches First Direct-to-Consumer Campaign for Qwo® (collagenase clostridium histolyticum-aaes) With 200+ Patient Events

Barclays has downgraded Endo International plc (NASDAQ: ENDP) from Equal-Weight to Underweight with a price target of $2, down from $5, on a 'difficult path.'  The analyst Balaji Prasad sees three headwinds for the company in 2022: lowered confidence on Qwo, weaker.

Barclays Downgrades Endo On 'Difficult Path'

The company's shares are down more than 36% so far this year.

Why Shares of Endo International Slumped 22.8% on Tuesday

Endo International plc (ENDP) CEO Blaise Coleman on Q4 2021 Results - Earnings Call Transcript

Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.

Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates

Endo International PLC (NASDAQ: ENDP) shares are trading lower after the company issued first-quarter EPS and sales guidance below analyst estimates. The company guided first-quarter EPS of $0.35 to $0.45 versus the consensus estimate of $0.48 and sales of $595 million to $635 million.

Why Endo International Shares Are Falling

DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance. "Endo's solid operational and financial performance in the fourth-quarter ended a year of strong performance across all of our business segments," said Blaise Coleman, President and Chief Executive Officer at Endo.

ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS

DUBLIN,, Feb. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it expects a Tennessee state court to issue an order granting plaintiffs' request for a default judgment on liability against Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, Endo or the Company) in Dunaway, et al. v. Purdue Pharma, L.P.

Endo Comments on Default Judgment on Liability in Tennessee State Court

In the latest trading session, Endo International (ENDP) closed at $3.14, marking a +1.95% move from the previous day.

Endo International (ENDP) Gains As Market Dips: What You Should Know

DUBLIN, Feb. 7, 2022 /PRNewswire/ -- First and only manufacturer-prepared, FDA approved vasopressin in a premixed ready-to-use (RTU) format RTU format does not require diluting, or transferring, which may reduce waste and chance of preparation error that could impact a patient's health Two-year shelf life1, with up to 12 months at room temperature2*, may offer enhanced health systems' inventory management Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping VASOSTRICT®, vasopressin injection, USP, in ready-to-use 100 mL pre-mix bottles. It's the first and only ready-to-use formulation of the drug.

Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Endo International (ENDP) closed at $3.21 in the latest trading session, marking a +0.63% move from the prior day.

Endo International (ENDP) Gains But Lags Market: What You Should Know

Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

Is Endo International (ENDP) a Great Stock for Value Investors?

DUBLIN, Jan. 25, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 4272796.

News for Endo International Stock (ENDP)